Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other central nervous system (CNS) disorders, announced today that Christopher U. Missling, PhD, has been appointed as President and CEO.
The conference will be broadcast live on the Anavex corporate website at www.anavex.com in the Investors section under “Events.” Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company focused on the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other CNS diseases, as well as pain and cancer.
Anavex previously received a research grant from the Michael J. Fox Foundation for Parkinson’s Research, which completely supported a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, a promising clinical stage therapeutic candidate that targets sigma-1 and muscarinic receptors, has shown disease-modifying effectiveness against the primary hallmarks of Alzheimer’s disease in transgenic mice, including cognitive impairments, amyloid, and tau pathology. ANAVEX®3-71 has proved to be effective against mitochondrial dysfunction and neuroinflammation in preclinical studies.